12th week of 2020 patent applcation highlights part 10 |
Patent application number | Title | Published |
20200085854 | COMPOSITION FOR USE IN THE TREATMENT OF EXTRAOESOPHAGEAL GASTRIC REFLUX SYMPTOMS - The present invention relates to a liquid mixture or solid mixture, in powder or granules, comprising or, alternatively, consisting of alginic acid and hyaluronic acid, or a salt thereof, for use in the treatment, in particular in the curative treatment, of extraoesophageal symptoms or disorders caused or provoked by gastroesophageal reflux (GERD) or by a partial reflux of gastric contents, such as, for example, the partial upflow of pepsin, hydrochloric acid, gastric juices or acidic gastric vapours from the stomach and wherein said disorders or symptoms manifest themselves in an extraoesophageal region. The present invention further relates to a liquid composition or solid composition, in powder or granules, which comprises said liquid or solid mixture comprising or, alternatively, consisting of alginic acid and hyaluronic acid, or a salt thereof, and optionally pharmaceutical or food grade additives or excipients, for use in the treatment, in particular in the curative treatment, of extraoesophageal disorders or symptoms that manifest themselves in the extraoesophageal region represented by the eye or eyeball and/or periocular region in patients affected by gastroesophageal reflux (GERD) or by a partial reflux of gastric contents, such as, for example, the partial upflow of pepsin, hydrochloric acid, gastric juices or acidic gastric vapours from the stomach. | 2020-03-19 |
20200085855 | DEVICE AND METHOD TO TREAT OR PREVENT JOINT DEGENERATION - A method for the delivery of aggrecan precursors to the joint of a subject, comprising the steps of: a) applying a composition comprising one or more aggrecan precursors chosen from the list comprising hyaluronic acid, glucosamine sulfate and/or chondroitin sulfate to the skin of the subject on or near a joint, wherein the composition is applied between the skin and a flexible magnetic film. | 2020-03-19 |
20200085856 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 2020-03-19 |
20200085857 | COMPOSITION FOR ALLEVIATING ATOPIC SKIN SYMPTOMS, CONTAINING POLY-GAMMA-GLUTAMIC ACID - Disclosed is a composition for alleviating symptoms of atopic dermatitis that contains a high molecular weight poly-gamma-glutamic acid and a low molecular weight poly-gamma-glutamic acid as active components. The composition for improving symptoms of atopic dermatitis inhibits epidermal and transepidermal water loss, improves desquamation (scaling skin), provides an excellent skin soothing effect, and relieves pruritus (itch) caused by dryness, thereby making remarkable improvement of general symptoms of atopic dermatitis. | 2020-03-19 |
20200085858 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING A PATHOGEN AND/OR MODIFYING MUCUS - Provided herein are compounds, compositions, and methods for modifying mucus, including modifying mucus using nitric oxide-releasing biopolymers (e.g., NO-releasing chitosan oligosaccharides). In some embodiments, a compound, composition, and/or method of the present invention modifies one or more properties of mucus to increase mucus clearance in a subject and/or prevents the growth or kills one or more pathogens present in mucus of a subject. | 2020-03-19 |
20200085859 | THERAPEUTIC POLYMER GEL SYSTEM TO PROMOTE HEALING AND PREVENT FIBROSIS AT A WOUND OR SURGICAL SITE - Disclosed herein are therapeutic polymer gel systems for promoting healing of a wound or surgical site in a subject. The therapeutic polymer gel forms a microporous network and may be applied or injected in a fluid form and annealed or crosslinked after application to the wound or surgical site. The microporous gel may optionally contain various therapeutic agents throughout the therapeutic polymer gel which are released. | 2020-03-19 |
20200085860 | COMPOSITION FOR PREVENTING OR TREATING SPINAL CORD INJURY COMPRISING IMIDAZOLE-POLY(ORGANOPHOSPHAZENE) HYDROGEL - The present disclosure relates to a pharmaceutical composition for preventing or treating spinal cord injury comprising an imidazole-poly(organophosphazene) hydrogel or a pharmaceutically acceptable salt thereof, a method for preventing or treating spinal cord injury, and a food composition for preventing or ameliorating spinal cord injury. | 2020-03-19 |
20200085861 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 2020-03-19 |
20200085862 | MULTIFUNCTIONAL LINKER TECHNOLOGY CONTAINING AN N4 GROUP - In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: | 2020-03-19 |
20200085863 | PHARMACEUTICAL FORMULA FOR THE TREATMENT AND/OR PREVENTION OF ARTHRITIS AND ITS MANUFACTURE - This invention discloses a pharmaceutical formula for arthritis treatment and/or prevention. The formula contains the following raw materials: a selenium-containing inorganic compound and a zinc-containing inorganic compound. The pharmaceutical formula described herein could be manufactured for topic application and provide a faster and safer treatment for various inflammatory joint pains. Pharmacodynamics results show that the invented pharmaceutical formula can significantly reduce the level of inflammatory cytokines in the joint synovial fluid in arthritis rabbit model, and the formulated ointment can achieve better efficacy compared with Voltaren™ (diclofenac) ointment; therefore the proposed formula has promising clinical application. | 2020-03-19 |
20200085864 | Stannous Fluoride Sugar Alcohol Solid Solutions - Stannous fluoride polyol solid solutions combine three complimentary, biochemical mechanisms attributed to Sn | 2020-03-19 |
20200085865 | Intramammary Veterinary Composition - A seal formulation for forming a physical barrier in the teat canal of a non-human animal comprises zinc oxide in a gel base. The seal formulation contains at least 40% by weight of the zinc oxide. | 2020-03-19 |
20200085866 | GALECTIN-3 PLASMAPHERESIS THERAPY - The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer. | 2020-03-19 |
20200085867 | GALECTIN-3 PLASMAPHERESIS THERAPY - The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer. | 2020-03-19 |
20200085868 | Method For Treating Cancer - The present disclosure relates to a method for treating cancer including steps as follows. A chemotherapy drug is administered to a subject in need for a treatment of cancer. Then a composition containing a plurality of chimeric antigen receptor expressing cells is administered to the subject, wherein the chimeric antigen receptor expressing cells expresses a chimeric antigen receptor specific to human leukocyte antigen G (HLA-G). | 2020-03-19 |
20200085869 | THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES - The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule. | 2020-03-19 |
20200085870 | PHARMACEUTICAL COMPOSITION AND METHODS COMPRISING IMMUNE CELLS AND PONATINIB - Methods and compositions for treating cancer are disclosed. The compositions comprise immune cells pretreated with ponatinib, or immune cells co-administered with ponatinib, where ponatinib promotes survival and anti-cancer cytotoxicity of the immune cells. | 2020-03-19 |
20200085871 | METHODS OF USING CYTOTOXIC T CELLS FOR TREATMENT OF AUTOIMMUNE DISEASES - The present disclosure relates to methods of using engineered cytotoxic T cells comprising a recombinant vector construct that expresses a chimeric antigen receptor to reduce and/or deplete the number of B cells in a subject in order to treat autoimmune diseases, such as lupus. | 2020-03-19 |
20200085872 | IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS - Provided herein are immune cells expressing antigenic receptors, such as a chimeric antigen receptor and a T cell receptor. Further provided herein are methods of treating immune-related disorder by administering the antigen-specific immune cells. | 2020-03-19 |
20200085873 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-03-19 |
20200085874 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-03-19 |
20200085875 | PLATELET VESICLE-ENGINEERED CELLS FOR TARGETED TISSUE REPAIR - Provided are engineered cells fused with platelet membrane vesicles and capable of specifically targeting a subendothelial site of vascular injury. Also provided are methods of generating a modified cell or extracellular vesicle fused with platelet membrane vesicles or fragments thereof. Further provided are methods for using these engineered cells and vesicles for the treatment of injured tissue accompanied by vascular injury by engraftment with modified cells fused with platelet membrane vesicles. Cells fused with the platelet vesicles can be engineered stem cells such as cardiac or mesenchymal stem cells; the extracellular vesicles fused with the platelet vesicles can be exosomes such as exosomes derived from cardiac or mesenchymal stem cells. The use of the platelet vesicles for targeting sites of vascular injury may also be usefully applied to engineering cells and exosomes that have therapeutic activity for the treatment of vascular injury. | 2020-03-19 |
20200085876 | IMMUNOMODULATING CELL CIRCUITS - Provided herein are methods and compositions for dynamically controlling and targeting multiple arms of the immune system. Some aspects provide mesenchymal stem cells (MSCs) engineered to produce multiple effector molecules. In some instances, each effector molecule modulates a different cell type of the immune system or different functions of a cell. Also provided herein are methods of using the MSCs to treat or alleviate symptoms of inflammatory bowel disease (IBD), for example. | 2020-03-19 |
20200085877 | ELESTOMERIC FIBROUS HYBRID SCAFFOLD FOR IN VITRO AND IN VIVO FORMATION - Biocompatible hybrid fibrous scaffold, derived from a synthetic polymer and a natural hydrogel, and methods of use thereof in tissue engineering. | 2020-03-19 |
20200085878 | PD-L1 EXPRESSING HEMATOPOIETIC STEM CELLS AND USES - Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE | 2020-03-19 |
20200085879 | METHOD FOR EFFICIENTLY PRODUCING 3D MIDBRAIN-LIKE ORGANOID THROUGH SPECIFIC ELECTROMAGNETIC WAVE PROCESSING - The present invention relates to a method of inducing differentiation into a 3D dopaminergic midbrain organoid using a specific electromagnetic wave. It was specifically identified that the method makes it possible to remarkably improve production efficiency of a dopaminergic neuronal 3D-differentiated organoid, from which symptoms of Parkinson's disease can be effectively alleviated. Thus, it is anticipated that the present invention is capable of making a more fundamental approach and achieving targeted therapies in the treatment of a cranial nerve disease. | 2020-03-19 |
20200085880 | METHODS AND COMPOSITIONS FOR ENHANCING CARDIOMYOCYTE MATURATION AND ENGRAFTMENT - Provided herein are methods and compositions comprising cardiomyocytes and epicardial cells for the treatment of cardiac disease. | 2020-03-19 |
20200085881 | TISSUE HEALING AGENT - The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition containing: adherent cells originating from mesenchymal tissue that has been treated with a physiologically active polypeptide or an LPS; and a pharmaceutically acceptable carrier. | 2020-03-19 |
20200085882 | METHODS FOR MEASURING THERAPEUTIC EFFECTS OF RETINAL DISEASE THERAPIES - Described herein are compositions and methods for treating retinal diseases or disorders using RPE cells. | 2020-03-19 |
20200085883 | METHODS OF SYNERGISTIC TREATMENT OF CANCER - A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated | 2020-03-19 |
20200085884 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH OF A GENETICALLY MODIFIED GUT BACTERIAL CELL - Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome. | 2020-03-19 |
20200085885 | PROBIOTIC COMPOSITIONS AND METHODS - The present invention relates to probiotic compositions and methods of using such compositions. In particular, the present invention provides methods of using | 2020-03-19 |
20200085886 | METHODS AND COMPOSITIONS FOR REDUCING LISTERIA MONOCYTOGENES INFECTION OR COLONIZATION - The disclosure relates to a therapeutic composition for treating | 2020-03-19 |
20200085887 | DIETARY SUPPLEMENTS CONTAINING PROBIOTICS - Dietary supplements comprising at least one probiotic and at least one of animal digest, dried brewers yeast, vitamin C; vitamin E, beta carotene, zinc proteinate, manganese proteinate, ferrous sulfate, copper proteinate, calcium iodate, and sodium selenite. The probiotics and other ingredients are present in the supplement in amounts sufficient to enhance the palatability of the probiotics and compositions containing the probiotics, enhance the immune system to augment the beneficial effects of the probiotics, or extend the life of the probiotics. | 2020-03-19 |
20200085888 | BACTERIA - The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders. | 2020-03-19 |
20200085889 | COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING METABOLIC SYNDROME - An object of the present invention is to provide a therapeutic composition for preventing, ameliorating, or treating metabolic syndrome. The present invention provides a composition for preventing, ameliorating, or treating metabolic syndrome, which composition contains | 2020-03-19 |
20200085890 | EXPRESSION OF PTEN-LONG WITH OCOLYTIC VIRUSES - Disclosed are novel modified viruses comprising recombinant PTEN-Long and methods of using the same for treating cancer. | 2020-03-19 |
20200085891 | ONCOLYTIC VACCINIA VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY - A pharmaceutical combination comprising (i) a replicative oncolytic vaccinia virus and (ii) an immune checkpoint protein inhibitor is provided as well as a kit comprising the pharmaceutical combination and methods for treating and/or preventing cancer. | 2020-03-19 |
20200085892 | USE OF ALPHAVIRUS IN PREPARATION OF ANTITUMOR DRUGS - Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes. | 2020-03-19 |
20200085893 | PREPARATION WITH THE MYCOPARASITIC MICROORGANISM PYTHIUM OLIGANDRUM FOR THE TREATMENT OF DERMAPHYTOSES AND YEAST INFECTIONS ON THE SKIN AND MUCOUSES, METHOD OF DETERMING THE CELL'S VIABILITY OF THE MICROORGANISM PYTHIUM OLIGANDRUM AND METHOD OF APPLYING THE PREPARATION - A preparation containing the mycoparasitic microorganism | 2020-03-19 |
20200085894 | TECOMA PLANT BASED COMPOSITIONS FOR TREATING SKIN LESIONS - A plant-based composition containing an alcohol extract of | 2020-03-19 |
20200085895 | PUNICALAGIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS ARISING FROM METHYLGLYOXAL-INDUCED DNA DAMAGE - The present invention provides in methods for reducing or inhibiting DNA damage in a cell. The methods administer compositions of at least a pomegranate polyphenol to reduce or inhibit DNA damage in the cell. | 2020-03-19 |
20200085896 | COMBINATION OF AQUEOUS EXTRACTS OF WATERCRESS AND NASTURTIUM AND ATP FOR USE IN THE TREATMENT OF ALOPECIA - The present invention relates to a novel combination comprising an extract of watercress, an extract of Indian cress, and ATP, and to the use of said combination in the field of hair science, more particularly in the treatment or prevention of alopecia. | 2020-03-19 |
20200085897 | Extract of Aerial Parts of Maca Rich in Polyphenols and Composition Comprising Same - The invention relates to an extract of aerial parts of Maca rich in polyphenols, and also to a composition comprising such an extract and, where appropriate, a suitable excipient. The invention also relates to a process for extracting an extract of aerial parts of Maca rich in polyphenols, and also to the extract that can be obtained by means of said process. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths and/or for use thereof in preventing and/or treating vascular disorders. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which comprises the administration of such a composition or of such an extract. | 2020-03-19 |
20200085898 | CUCUMIS SATIVUS L. EXTRACT FOR USE IN THE TREATMENT AND/OR PREVENTION OF ENTEROPATHIES, PARTICULARLY OF INFLAMMATORY ORIGIN, IN PETS, AND FEED CONTAINING SUCH EXTRACT | 2020-03-19 |
20200085899 | METHOD FOR TREATING VITILIGO - A first embodiment of a composition for treating vitiligo includes | 2020-03-19 |
20200085900 | METHOD OF USING A ROSEMARY EXTRACT COMPOSITION FOR WEIGHT MANAGEMENT - A method of modulating body weight using a composition of rosemary extract having a pre-determined amount of ursolic acid. | 2020-03-19 |
20200085901 | PROCESS FOR THE PREPARATION OF POWDER COMPOSITIONS - Disclosed is a process for the preparation of powder compositions including a lipophilic extract of | 2020-03-19 |
20200085902 | COMPOSITION AND METHOD FOR TREATING ITCHING, BURNING AND DISCOMFORT OF THE SKIN - A topical composition for treating discomfort of the skin and mucous membranes comprising therapeutically effective amounts of | 2020-03-19 |
20200085903 | Protective Effects of Oil Palm Composition on Alzheimer's Disease - Present invention discloses an oil palm composition for use in prevention or treatment of Alzheimer's disease. The composition is useful in impeding formation of neurotoxic peptide. Present invention can be used in preparation of a medicament in a therapeutic effective amount for prevention or treatment of Alzheimer's disease and diseases related thereto. | 2020-03-19 |
20200085904 | HERBAL COMPOSITION - The present invention generally relates to an herbal composition effective in management of disorders related to metabolic syndrome. More particularly, the invention relates to an herbal composition effective in the management of disorders related to metabolic syndrome such as Type 2 diabetes mellitus, obesity and lipid profile management and a process for the preparation of such an herbal composition. The invention further relates to the use of the herbal composition in preparation of food supplements, pharmaceuticals and nutraceuticals for the management of disorders related to metabolic syndrome. The herbal composition effective in management of metabolic syndrome related disorders comprises of herbs selected from | 2020-03-19 |
20200085905 | METHOD OF TREATING OVERWEIGHT OR OBESITY COMPRISING ADMINISTERING A PLEUROTUS OSTREATUS MUSHROOM EXTRACT OR A COMPOSITION COMPRISING A PLEUROTUS OSTRETUS MUSHROOM EXTRACT - Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof. | 2020-03-19 |
20200085906 | THE USE OF SUBSTANCES FOR THE TREATMENT OF LOSS OF EYESIGHT IN HUMANS WITH GLAUCOMA AND OTHER DEGENERATIVE EYE DISEASES - Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof. | 2020-03-19 |
20200085907 | ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS - Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof. | 2020-03-19 |
20200085908 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF - Methods for treating solid tumor, determined to lack a p53 deactivation mutation, in a subject are provided. Also provided are peptidomimetic macrocycles for use in treatment of a solid tumor, determined to lack a p53 deactivation mutation, in a subject. | 2020-03-19 |
20200085909 | BUCKWHEAT HONEY AND BACITRACIN WOULD-HEALING DRESSING - A wound healing composition and method for treating acute and chronic wounds and skin conditions includes a wound healing composition or formulation including a mixture of buckwheat honey, methylglyoxal and bacitracin. | 2020-03-19 |
20200085910 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF - The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided. | 2020-03-19 |
20200085911 | TRANSGENIC CORN WITH ANTIFUNGAL PEPTIDE AGM182 USDA (DN:0113.18) - is an opportunistic, saprophytic fungus that infects maize and other fatty acid-rich food and feed crops and produces toxic and carcinogenic secondary metabolites known as aflatoxins. In vitro studies showed a five-fold increase in antifungal activity of AGM182 (vs. tachyplesin1) against | 2020-03-19 |
20200085912 | Compositions and Methods for Treating Inflammation and Cancer - The present invention provides compositions and methods for selective inhibition of the classical or non-classical LTβR-NFκB signaling pathway. In some embodiments, the compositions and methods of the present invention are useful for treating or preventing tissue graft rejection, inflammation, contact hypersensitivity, and cancer by decreasing cell motility. | 2020-03-19 |
20200085913 | PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE - Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs. | 2020-03-19 |
20200085914 | COMPOSITIONS AND METHODS FOR WOUND HEALING - Compositions of insulin-secreting cells and stem cells and methods for their use as well as use of insulin and stem cell products in wound healing and/or reducing scar and/or scab formation are provided. | 2020-03-19 |
20200085915 | METHODS OF INDUCING IMMUNE TOLERANCE TO CLOTTING FACTORS - The present disclosure provides methods inducing immune tolerance in a human, comprising administering to the human an effective amount of a composition or a chimeric protein comprising a clotting factor and an Fc region. | 2020-03-19 |
20200085916 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA - The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA). | 2020-03-19 |
20200085917 | MUTANT HUNTINGTIN-MEDIATED PROTEIN DYSFUNCTION - The present invention relates to methods of inhibiting neurodegeneration in a subject suffering from or genetically at risk and/or destined to develop Huntington's Disease comprising increasing, in neurons of the subject, the activity of the TIM23 mitochondrial protein import complex. | 2020-03-19 |
20200085918 | COMPOSITIONS AND METHODS FOR TREATMENT OF UREMIC CARDIOMYOPATHY - Methods for treating uremic cardiomyopathy are provided and include the step of administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. The polypeptide anatagonist can further include a cell penetrating polypeptide. Methods of treating anemia, including anemia-associated with chronic kidney disease, are also provided. | 2020-03-19 |
20200085919 | BIOFILM DISRUPTING COMPOSITION FOR USE ON CHRONIC WOUNDS - A biofilm disrupting composition for use on chronic wounds comprising (i) at least one biologically acceptable thiol based antioxidant(ii) at least one biofilm disruptor and (iii) at least one biocide. Also disclosed is a process of preparing the composition. Also disclosed is the use of the composition for the manufacture of a medicament for the treatment of a chronic wound, and a method of treating a chronic wound in a patient comprising administering the biofilm disrupting composition. | 2020-03-19 |
20200085920 | METHOD FOR PREVENTING AND TREATING FATTY LIVER - The present invention relates to a method for preventing and/or treating fatty liver and its related conditions in a subject, comprising administering an effective amount of plasminogen to the subject; in another aspect, the present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating fatty liver and its related conditions in the subject. | 2020-03-19 |
20200085921 | COMBINATION THERAPIES - The invention provides combination therapy for use in treating a bacterial biofilm in a subject comprising (a) a polypeptide having serine protease activity and (b) one or more antibiotic compounds. Also provided are compositions and methods of use of the same. | 2020-03-19 |
20200085922 | METHODS AND COMPOSITIONS RELATED TO A TISSUE FACTOR-TARGETING IGG3 IMMUNOCONJUGATES - Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate protein, wherein said immunoconjugate protein comprises a hybrid Fc region of an IgG1 and an IgG3 immunoglobulin conjugated to Factor VII. These immunoconjugates can target Tissue Factor (TF) expressing cells. | 2020-03-19 |
20200085923 | METHODS FOR TREATMENT OF MASSETER MUSCLE HYPERTROPHY - Methods and kits for treating or alleviating masseter muscle hypertrophy by local administration of a Clostridial derivative, such as a botulinum toxin, to the masseter muscle are described. Methods and kits for reducing lower face width and for reducing prominence of the masseter muscle of a human are also described. | 2020-03-19 |
20200085924 | PHARMACEUTICAL COMPOSITION FOR TREATING FOOT PAIN DISEASE INCLUDING BOTULINUM TOXIN AND HYALURONIC ACID, AND FOOT PAIN DISEASE TREATMENT METHOD USING SAME - The present invention relates to a pharmaceutical composition for treating a foot pain disease, including botulinum toxin and hyaluronic acid, and a foot pain disease treatment method using the same. More specifically, the composition according to the present invention can exhibit a synergistic action of increasing both anti-inflammatory and anti-pain activity through an inflammation-inhibiting effect on a foot pain disease such as pain arising from plantar fasciitis, foot fasciitis, Achilles tendon damage, flat feet, diabetes, and gout. Thus, the composition according to the present invention is expected to be able to be usefully used subcutaneously in the foot as a liquid injection agent that exhibits an effect of treating or alleviating a foot pain disease. | 2020-03-19 |
20200085925 | COMPOSITIONS AND METHODS FOR TREATING NRP2-ASSOCIATED DISEASES - Provided are therapies, including standalone and combination therapies, for treating neuropilin-2 (NRP2)-associated diseases and conditions, which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide. | 2020-03-19 |
20200085926 | ANTIGEN FUSED WITH PORCINE FC FRAGMENT AND VACCINE COMPOSITION COMPRISING THE SAME - Provided is an antigen fused with a porcine Fc fragment, a vaccine composition having a self-adjuvanting effect by binding an Fc fragment to various antigens, and a method of producing the antigen. | 2020-03-19 |
20200085927 | COMPOUND COMPRISING AN AUTOANTIGENIC PEPTIDE AND A CARRIER WITH A MHC BINDING MOTIF - The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated. | 2020-03-19 |
20200085928 | NOVEL PD-L1 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY - The present invention relates to an attenuated strain of | 2020-03-19 |
20200085929 | HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS - The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment. | 2020-03-19 |
20200085930 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-03-19 |
20200085931 | PROTEIN NANOPARTICLES AND COMBINATION THERAPY FOR CANCER IMMUNOTHERAPY - Cancer-testis antigens were simultaneously packaged with CpG adjuvant and incorporated into an E2 nanoparticle platform to increase cancer vaccine efficacy. Also described herein is a combination of checkpoint blockade therapy and the nanoparticle vaccine platform to deliver cancer antigens with adjuvant for treatment of tumors and prevention of future tumors. The nanoparticle vaccine platform includes a protein capsule to which are attached adjuvants in the internal hollow cavity and cancer epitopes to the surface. Whereas single-therapies only increase survival, the combined therapy can both increase survival time as well as prevent tumor development in pre-existing tumor conditions by increasing tumor antigen-specific responses (via the nanoparticle vaccines) while simultaneously blocking checkpoints to remove immune suppression (via immune checkpoint inhibition). Furthermore, tumor re-challenge studies show evidence of T cell memory which can prevent tumor development in some individuals. | 2020-03-19 |
20200085932 | Methods and Compositions Using Highly Conserved Pneumococcal Surface Proteins - Cold spot genes of | 2020-03-19 |
20200085933 | Bordetella vaccines comprising LPS with reduced reactogenicity - The current invention lies in the field of medicine and more specifically in the field of vaccinology. The current invention concerns a novel | 2020-03-19 |
20200085934 | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES AGAINST CLOSTRIDIUM DIFFICILE - Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards | 2020-03-19 |
20200085935 | COMBINATION VACCINE FOR SWINE - The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV. | 2020-03-19 |
20200085936 | VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME - Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein. | 2020-03-19 |
20200085937 | VLP-BASED MONOVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME - Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen. | 2020-03-19 |
20200085938 | Virus Like Particle Compositions and Methods of Use - The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases. | 2020-03-19 |
20200085939 | DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES - A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines. | 2020-03-19 |
20200085940 | METHODS FOR ENTEROVIRUS INACTIVATION, ADJUVANT ADSORPTION AND DOSE REDUCED VACCINE COMPOSITIONS OBTAINED THEREOF - The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions. | 2020-03-19 |
20200085941 | ANTIGENIC THERMOSTABLE POLIO VACCINES & RELATED METHODS - The disclosure concerns vaccines; and more particularly, highly antigenic thermostable vaccines configured for mucosal or transdermal delivery without reconstitution. Also disclosed are methods for formulating the highly antigenic thermostable vaccines. | 2020-03-19 |
20200085942 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT - The present invention relates to nucleic acids of the general formula (I): (N | 2020-03-19 |
20200085943 | PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN - The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases. | 2020-03-19 |
20200085944 | RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY - The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides a combination of an RNA encoding an epitope and immune checkpoint inhibitors. A pharmaceutical composition, vaccine, and kit-of-parts comprising said combination are also provided. Furthermore, the present invention relates to the combination, (pharmaceutical) composition, vaccine or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of cancer, infectious diseases and other diseases and disorders. | 2020-03-19 |
20200085945 | Methods of Treating Palmoplantar Pustular Psoriasis (PPP) Using IL-17 Antagonists - The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter cilia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab. | 2020-03-19 |
20200085946 | MONOCLONAL ANTIBODIES TO HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 2 (HFGFR2) AND METHODS OF USE THEREOF - The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2). | 2020-03-19 |
20200085947 | VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER - The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1). | 2020-03-19 |
20200085948 | LIQUID PHARMACEUTICAL COMPOSITION - The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug. | 2020-03-19 |
20200085949 | MICROCAPSULE HAVING A MICROCAPSULE SHELL MATERIAL THAT IS RUPTURABLE VIA A RETRO-DIMERIZATION REACTION - A microcapsule encapsulates a payload agent, the microcapsule having a microcapsule shell material that is rupturable (e.g., to release the encapsulated payload agent) via a retro-dimerization reaction. | 2020-03-19 |
20200085950 | PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES - The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm | 2020-03-19 |
20200085951 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2020-03-19 |
20200085952 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2020-03-19 |
20200085953 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2020-03-19 |